Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25737103 | 0.87 | DHODH (0.55) | KDM4ESMN1; SMN2LMNAPDE10ADHODH | |
| SCHEMBL3041657 | 0.83 | KDM4E (0.57) | KDM4ESMN1; SMN2LMNAPDE10ADHODH | |
| SCHEMBL10869696 | 0.81 | KDM4E (0.55) | KDM4ESMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL26627263 | 0.81 | ESR1 (0.48) | KDM4ESMN1; SMN2DHODHPOLBMEN1 | |
| SCHEMBL10018550 | 0.80 | DHODH (0.60) | KDM4ESMN1; SMN2DHODHPOLBKMT2A | |
| SCHEMBL25735933 | 0.80 | RXFP1 (0.56) | KDM4ESMN1; SMN2DHODHPOLBNPC1 | |
| SCHEMBL30595092 | 0.79 | KDM4E (0.80) | KDM4ESMN1; SMN2LMNAPDE10ADHODH | |
| SCHEMBL374558 | 0.79 | KDM4E (0.80) | KDM4ESMN1; SMN2LMNAPDE10ADHODH | |
| SCHEMBL29727188 | 0.77 | L3MBTL1 (0.67) | KDM4ESMN1; SMN2LMNAPDE10ADHODH | |
| SCHEMBL1305492 | 0.77 | L3MBTL1 (0.67) | KDM4ESMN1; SMN2LMNAPDE10ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20100113492-A1 | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113492-A1 | Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators | CCKAR, CCKBR, GLP1R | KDM4E 3052/4885SMN1; SMN2 4390/4885LMNA 4852/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | KDM4E 2788/4885SMN1; SMN2 3607/4885LMNA 4027/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | KDM4E 2301/4885SMN1; SMN2 3469/4885LMNA 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.